Epidemiological characterization of SARS-CoV-2 outbreaks in three nursing homes
For the largest of the three outbreaks (nursing home A), the first infection was documented in the dementia ward on May 17, 2021, for an 89-year-old woman who developed COVID-19-related symptoms, was subsequently hospitalized and succumbed after two weeks of hospitalization. An additional 101 cases were documented related to this outbreak between May 18 and June 24, of which 75 were residents, 25 staff members and 2 family members of staff. All departments of the nursing home were involved, and consecutive screening moments were scheduled. Among 120 residents, 75 were SARS-CoV-2 positive by PCR (62.5%, Table 1), whereas only 25 out of 146 (17.1%) staff members tested positive (Supplementary Table 1). Timing of diagnosis by a positive PCR result and longitudinal follow-up is illustrated in Figure 1A, which clearly illustrates delayed PCR-positivity for a large subset of residents who tested PCR-negative at the start of the outbreak. This “second wave” of delayed infections was corroborated by the continuous detection of SARS-CoV-2 by qPCR in aerosol samples taken from the common areas of both staff and residents (Figure 1B). For 59.2% of positive cases, WGS information was available, identifying the Delta variant (Pangolin lineage B.1.617.2) for all of them. Phylogenetic analysis indicates that all samples from the nursing home cluster within the same clade, hence suggesting a single introduction event (Figure 1C). Among the 102 PCR positive cases, 15 residents died (case fatality ratio of 14.7%). Considering all individuals for which vaccination status was known (Table 1), 96% of residents but only 66% of staff members were fully vaccinated. One resident and five staff members were partially vaccinated at the time of the outbreak, while one resident and 28.7% of staff members were not vaccinated.
The first documented PCR-positive case for nursing home B dates from May 20, 2021, while the presumed index case developed COVID-19 symptoms the day before. Overall, 19 out of 29 residents (65.5%) tested positive for SARS-CoV-2, but none of the 17 staff members tested positive on the repetitive screening moments organized between May 20 and June 24. WGS classified the circulating virus as the Gamma variant (Pangolin lineage P.1). Our phylogenetic analysis highlights that all samples cluster together within the more global Gamma phylogeny inferred in our study, again pointing towards the hypothesis of a single introduction event (Supplementary Figure 1). Overall, 7 fatal cases were reported in this outbreak, of which one resident tested negative by PCR. However, this death was classified as COVID-19-related due to severe respiratory symptoms and recent close contact with positive residents. For this nursing home, the vaccination rate was high among residents (86.2%), while only 52.9% of the staff members were fully vaccinated at the time of the outbreak. Nevertheless, none of them tested positive for SARS-CoV-2.
The post-vaccination outbreak in nursing home C was initially alerted by two cases (related resident and staff) infected with the Delta variant a few days prior to the large testing initiative for the other residents and staff members planned on July 20, 2021. Twenty-five additional SARS-CoV-2 positive cases were identified during the outbreak. WGS determined the presence of the variant of interest Mu (Pangolin lineage B.1.621), complemented with the mutation K417N in the spike protein, while for one isolated case (staff member without resident contact), an additional Delta infection was identified. The three Delta cases are therefore not considered for the description of the outbreak (Table 1). The Mu variant saw relatively limited circulation in Belgium, resulting in a restricted sampling of related genomic sequences in the local community. Our phylogenetic analysis however indicates that infectious cases in this nursing home related to that variant clearly cluster within the overall phylogeny inferred for that variant (Supplementary Figure 2), again advocating for a single introduction event. Among the 24 PCR-positive cases infected with variant Mu, 20 residents and four staff members were involved, all linked to the dementia unit of the nursing home. Overall, seven infected residents died, while one additional resident died of a COVID-19-unrelated cause. The final SARS-CoV-2 infection was diagnosed on August 10, 2021. Considering the 229 residents and staff members with known vaccination status, the overall vaccination rate was 98.3%. For the group of PCR-positive residents, 100% were fully vaccinated.
Demographic and clinical characterization of SARS-CoV-2 outbreaks in three nursing homes
Demographic and clinical risk factors for fatal COVID-19 were identified by multivariable logistic regression models (Table 2), with the best model including age, male sex, non-Delta SARS-CoV-2 variants (Gamma/Mu), and later timing of infection (PCR-positivity >7 days after start of the outbreak). In the sensitivity analysis, only fully vaccinated and PCR-positive residents (n=107) were included. The results remained statistically significant, with a similar effect size (Supplementary Table 2). The importance of these four factors as predictors of mortality was confirmed by Kaplan-Meier survival estimates (Supplementary Figure 3) and time-to-event analysis (Cox Proportional Hazard regression, Supplementary Table 3). Of interest, dementia or peak viral load (nadir Cq value) were not predictive of fatal cases in the joint analysis of the three outbreaks (Table 2) but were significant predictors in single nursing homes (Supplementary Table 3).
Virological and immunological characterization of SARS-CoV-2 outbreaks in three nursing homes
In search of candidate biomarkers for post-vaccine fatal COVID-19, as well as possible novel therapeutic targets, we opted for nCounter digital transcriptomics for immunovirological profiling of the nasal mucosa, encouraged by previous results22-24. For 20 out of 28 fatal cases, a sufficient volume of diagnostic nasopharyngeal swabs was available for nCounter analysis, to explore immunological (600 genes representative of the major immune cell types) and virological parameters (SARS-CoV-2 transcripts and ACE2/TMPRSS2 receptors) as possible risk factors for fatal post-vaccine COVID-19. Thus, we carefully matched (age, sex, outbreak) 20 fatal cases (all those with available nasopharyngeal swabs) with 30 PCR-positive non-fatal cases, with similar timing of infection, as well as 10 PCR-negative but SARS-CoV-2-exposed residents.
As shown in Figure 2 (Volcano plot), a total of 193 human and 7 viral gene transcripts were significantly up- or down-regulated (p<0.05) when comparing fatal vs. non-fatal cases. In addition to the antiviral cytokines IL28A (also known as IFNL2, interferon-λ2) and IFNB1 (the gene encoding interferon-beta, IFN-β), the most upregulated genes were predominantly expressed by innate immune cells: monocytes/macrophages (CX3CR1, TNFSF15, CLEC6A, ITLN1, LILRB5), Natural Killer (NK) cells (THY1, CDH5, KIR3DL3, CD160, B3GAT1, NCAM1, CCL3) and conventional dendritic cells (XCR1). Thus, the predominant immunopathogenic signature of fatal COVID-19 in vaccinated residents represents exacerbated innate immune activation, rather than a failed adaptive (B and T-cell) vaccine response. Surprisingly, a large subset of B-cell genes (CD19, CR2, CD79A, CD79B, PAX5, CD70), regulatory T-cell (Treg) genes (FOXP3, PTGER4) and cytotoxic CD8 T-cell genes (EOMES, PTGER4) were also significantly up-regulated in fatal cases, arguing against a curtailed B- or T-cell response or a failure of B or T-cells to migrate to the nasal mucosa. Since the top down-regulated genes were most representative of mucosal epithelial cells (PIGR, CD9, MUC1), the observed exacerbated innate response might represent enhanced migration of innate immune cells but also virus-mediated destruction of the mucosal epithelial cells.
In favor of the latter hypothesis, fatal cases were characterized by significantly higher viral transcript levels, when measured by nCounter. Transcript levels for Spike, Envelope, Nucleoprotein, ORF1ab, ORF3a and ORF7a genes (Figure 3A and data not shown, all p<0.05 with False Discovery Rate (FDR) correction), were higher in fatal cases compared to non-fatal PCR-positive residents. In addition, antisense SARS-CoV-2 was selectively increased in 8 out of 20 fatal cases (Figure 3A) versus PCR-positive cases, indicating heightened intracellular viral replication. Of note, peak viral load (nadir Cq values) or viral load of the first PCR-positive sample, measured by qPCR, were not significantly different between fatal cases and PCR-positive controls (Figure 3A), underscoring the sensitivity of nCounter digital transcriptomics. Exacerbated viral replication in fatal cases was paralleled by a marked eightfold increase in viral receptor ACE2 transcript levels (p<0.001), as well as an unexpected two-fold decrease (p<0.01) in viral co-receptor TMPRSS2 expression (Figure 3B).
Among all immune genes, IFNB1 transcripts displayed the strongest negative correlation to survival time (starting from the date of PCR-positive diagnosis, Spearman’s ρ=-0.24, p=0.0024). Corroborating our previous findings in a Belgian cohort of ICU patients,22 we found that increased IFNB1 transcript levels significantly predicted a fatal outcome (Figure 3C-D, AUROC 0.76 (95%CI 0.63-0.89), p=0.0013), which was only slightly increased by adding age and sex to the model (Figure 3D, AUROC 0.80 (95%CI 0.69-0.92), p=0.0002). IFNB1 remained a significant predictor in multivariable logistic regression, independent of age, sex and peak viral load (nadir Cq value), which was also confirmed by time-to-event analysis (Cox Proportional Hazard models, Table 3), and was replicated when Delta and non-Delta (Gamma/Mu) outbreaks were analyzed separately (Supplementary Table 3).
Lastly, when combining all available demographic, immune and viral parameters, the best predictive model for mortality, according to the corrected Akaike’s Information criterion (AICc), included age (OR 1.07, 95%CI 0.98-1.19), increased viral ORF7a (OR 1.67 95%CI 0.98-3.46) and viral receptor ACE2 (15.43 95%CI 2.54-165.9) transcript levels, resulting in correct classification of 18 out of 20 (90%) fatal cases (AUROC 0.87, 95%CI 077-0.97, p<0.0001), as visualized in Figure 3D.
Comparison with published pre-vaccine fatal COVID-19 signatures and reanalysis of single-cell RNAseq data highlights the unique immune signature in post-vaccination fatal COVID-19 outbreaks
To our knowledge, this is the first well-powered study of immune signatures in post-vaccination fatal COVID-19 in the elderly. Thus, no public datasets are currently available for independent validation of our newly derived immune signature in a comparable epidemiological setting. Therefore, we compared published gene signatures of pre-vaccination fatal COVID-19 in nasal mucosa and matched whole blood samples25. In addition, we reanalyzed publicly available single-cell RNAseq data from nasal mucosa of patients with moderate and critical COVID-1926 and PBMCs from critical and fatal COVID-19 cases27, all from the pre-vaccination era.
As shown in Figure 4A, there was surprisingly little overlap between our “post-vaccine” fatal COVID-19 signature (nasal swabs) and “pre-vaccine” fatal COVID-19 gene signatures (bulk RNAseq) from either nasal swabs or whole blood, the latter comparing fatal vs. non-fatal hospitalized COVID-19 patients. No differentially expressed gene was shared among the three datasets, while only six and 15 genes were shared between our “post-vaccine” fatal signature and the “pre-vaccine” nasal swab and whole blood gene fatal signatures, respectively (Figure 4A, middle panel). Moreover, directionality was opposite (up- vs. down-regulation) for 5 out of 6 nasal mucosa genes (Figure 4A left panel) and 4 out of 15 whole blood genes (Figure 4A right panel), and fold-changes were not correlated (p=0.42 and p=0.98, respectively, data not shown).
Reanalysis of publicly available single-cell RNAseq data shows cell-specific expression of the strongest up-regulated genes in fatal cases: TNFSF15 in neutrophils (Neu) and non-resident macrophages (nrMA), PTGER4 in neutrophils and Treg, CX3CR1 in resident (rMa) and non-resident macrophages (nrMa), CR2 in B-cells, ACE2 in several epithelial cell types (Figure 4B). Of these, most findings of gene- and/or cell-specific up-regulation with disease severity were replicated between both nasal mucosa datasets (Figure 4C, upper panel), i.e. up-regulation in post-vaccine fatal cases (this study) as well as in critical vs. moderate COVID-19 (pre-vaccine era), with the exception of CX3CR1. In addition, increased EOMES expression in cytotoxic CD8 T-cells (CTL) was also replicated in critical vs. moderate COVID-19 (Figure 4C, lower panel). However, divergent expression between post-vaccine (fatal COVID-19, this study) and pre-vaccine data sets (moderate vs critical COVID-19) was observed for CDH5 and THY1 in NK cells (not increased in critical COVID-19). Furthermore, IFNB1 and MASP2 transcripts were undetectable by single-cell RNAseq analysis of both nasal mucosa26 (Figure 4C, lower panel) and PBMCs27 (data not shown) from COVID-19 patients, again underscoring the sensitivity of nCounter digital transcriptomics for low-abundance transcripts. As shown in Suppl. Figure 4, top genes downregulated in fatal cases were most expressed in epithelial cell types (PIGR, MUC1, CD9, CD46), in agreement with our virus-mediated mucosal epithelium destruction hypothesis (Figure 2-3). On the other hand, a generalized down-regulation of MHC class I-mediated antigen presentation (B2M, HLA-C) was observed across all cell types, in agreement with previous reports demonstrating loss of MHC class I activity at the transcriptomic, epigenomic and functional level25-30.
Taken together, cross-examination of published pre-vaccine fatal COVID-19 signatures and reanalysis of single-cell RNAseq data highlights the unique innate and adaptive immune signature observed in post-vaccination fatal COVID-19 in nursing home residents.